Related to Galapagos Achieves $7.3M Milestone in Osteoarthritis Deal with GSK

• GSK and Crucell Team Up to Develop a Prime-Boost Malaria Vaccine
  
• GSK Taps Activiomics to Research Inflammatory Signaling Mechanisms
  
• GSK and EyeGate to Evaluate Iontophoresis System for Drug Delivery to Eye Tissues
  
• GSK Pays £73.9M for Nearly 10% Stake in Korean Firm Dong-A
  
• GSK and Prosensa Expand Ongoing Exon-Skipping DMD Therapeutics Alliance
  
• NIH Prolongs Compound-Management Arrangement with Galapagos Until End of 2012
  
• Lonza to Manufacture HGS and GSK’s Lupus Drug Benlysta
  
• Bristol University Teams Up with Galapagos to Develop Neuropathic Pain Therapy
  
• GSK Taps NCCN to Conduct Cancer Clinical Testing for $4M
  
• Isis Earns $5M Milestone from GSK Five Months into RNA Therapeutics Partnership
  
• GSK Pays FivePrime $15M to Initiate Skeletal Muscle Disorder Collaboration
  
• Amplimmune Gets $23M Up Front from GSK to Develop PD-1-Targeting Drugs
  
• Nabi Scores Another $8M from GSK under MRSA Vaccine Deal
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• GSK Obtains Rights to Delphi’s Antibiotic-Free Tech for Recombinant Vaccines
  
• Prosensa Earns £7.5M Milestone from GSK through Antisense DMD Drug Deal
  
• Galapagos Wins €3.7M IWT Grant to Develop Cystic Fibrosis Therapeutics
  
• GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug
  
• GSK Reports Japanese Clearance for ITP Drug as Partner Ligand Gets $2M in Govt Grants